Transdermal delivery of PeptiCRAd cancer vaccine using microneedle patches
Source abstract
Abstract
Microneedles (MNs) are a prospective system in cancer immunotherapy to overcome barriers regarding proper antigen delivery and presentation. This study aims at identifying the potential of MNs for the delivery of Peptide-coated Conditionally Replicating Adenoviruses (PeptiCRAd), whereby peptides enhance the immunogenic properties of adenoviruses presenting tumor associated antigens. The combination of PeptiCRAd with MNs containing polyvinylpyrrolidone and sucrose was tested for the preservation of structure, induction of immune response, and tumor eradication. The findings indicated that MN-delivered PeptiCRAd was effective in peptide presentation in vivo, leading to complete tumor rejection when mice were pre-vaccinated. A rise in the cDC1 population in the lymph nodes of the MN treated mice led to an increase in the effector memory T cells in the body. Thus, the results of this study demonstrate that the combination of MN technology with PeptiCRAd may provide a safer, more tolerable, and efficient approach to cancer immunotherapy, potentially translatable to other therapeutic applications.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Advancements in Transdermal Drug Delivery · Toxin Mechanisms and Immunotoxins · Immunotherapy and Immune Responses
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (58)
Show source-provided references
1. A guide to cancer immunotherapy: from T cell basic science to clinical practice10.1038/s41577-020-0306-5 ↗
2. Personalized cancer vaccines: clinical landscape, challenges, and opportunities10.1016/j.ymthe.2020.09.038 ↗
3. Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges10.1038/s41571-019-0308-z ↗
4. Vaccine therapies for cancer: then and now10.1007/s11523-020-00788-w ↗
5. Enhanced cancer immunotherapy by microneedle patch-assisted delivery of HBc VLPs based cancer vaccine
6. Dissolving microneedles for transdermal drug delivery10.1016/j.biomaterials.2007.12.048 ↗
7. Microneedles for transdermal drug delivery10.1016/j.addr.2003.10.023 ↗
8. Microneedles for drug and vaccine delivery10.1016/j.addr.2012.04.005 ↗
9. Influenza virus-like particles coated onto microneedles can elicit stimulatory effects on Langerhans cells in human skin10.1016/j.vaccine.2010.05.055 ↗
10. Enhancing influenza vaccine immunogenicity and efficacy through infection mimicry using silk microneedles10.1016/j.vaccine.2021.07.064 ↗
11. Exploiting unique features of microneedles to modulate immunity10.1002/adma.202302410 ↗
12. A single‐administration microneedle skin patch for multi‐burst release of vaccine against SARS‐CoV‐210.1002/admt.202200905 ↗
13. Biodegradable microneedle patch delivering antigenic peptide–hyaluronate conjugate for cancer immunotherapy10.1021/acsbiomaterials.9b00961 ↗
14. Prevalence of pain and fear as barriers to vaccination in children – systematic review and meta-analysis10.1016/j.vaccine.2022.10.026 ↗
15. Microneedle patches for vaccination in developing countries10.1016/j.jconrel.2015.11.019 ↗
16. Considerations in the use of microneedles: pain, convenience, anxiety and safety10.1080/1061186X.2016.1200589 ↗
17. Microneedle patches: usability and acceptability for self-vaccination against influenza10.1016/j.vaccine.2014.01.076 ↗
18. The promise of microneedle technologies for drug delivery
19. Peptides-coated oncolytic vaccines for cancer personalized medicine10.3389/fimmu.2022.826164 ↗
20. Cancer-targeted oncolytic adenoviruses for modulation of the immune system10.2174/1568009617666170502152352 ↗
21. Characterization of a novel OX40 ligand and CD40 ligand-expressing oncolytic adenovirus used in the PeptiCRAd cancer vaccine platform10.1016/j.omto.2021.02.006 ↗
22. Polyvinylpyrrolidone microneedles enable delivery of intact proteins for diagnostic and therapeutic applications10.1016/j.actbio.2013.04.045 ↗
23. PVP-microneedle array for drug delivery: mechanical insight, biodegradation, and recent advances10.1080/09205063.2022.2155778 ↗
24. Double‐layered polyvinylpyrrolidone–poly(methyl vinyl ether‐ alt ‐maleic acid)‐based microneedles to deliver meloxicam: an in vitro, in vivo, and short‐term stability evaluation study10.1002/adtp.202300138 ↗
25. Transdermal delivery of pramipexole using microneedle technology for the potential treatment of Parkinson's disease10.1021/acs.molpharmaceut.4c00065 ↗
26. Development and characterisation of novel poly (vinyl alcohol)/poly (vinyl pyrrolidone)-based hydrogel-forming microneedle arrays for enhanced and sustained transdermal delivery of methotrexate10.1016/j.ijpharm.2020.119580 ↗
27. Potential of trehalose and sucrose-raffinose combination instead of sucrose applied to the cytarabine/daunorubicin co-loaded lyophilized liposome: Investigation on the protective effect and mechanism of various lyoprotectants
28. Self‐healing encapsulation and controlled release of vaccine antigens from PLGA microparticles delivered by microneedle patches10.1002/btm2.10103 ↗
29. Long-term thermostabilization of live poxviral and adenoviral vaccine vectors at supraphysiological temperatures in carbohydrate glass10.1126/scitranslmed.3000490 ↗
30. Structural stability of adenovirus type 510.1002/jps.10340 ↗
31. The role of type 1 conventional dendritic cells in cancer immunity10.1016/j.trecan.2018.09.001 ↗
32. Are conventional type 1 dendritic cells critical for protective antitumor immunity and how?10.3389/fimmu.2019.00009 ↗
33. Combinatorial treatment with oncolytic adenovirus and helper-dependent adenovirus augments adenoviral cancer gene therapy10.1038/mto.2014.8 ↗
34. An oncolytic adenovirus enhanced for toll-like receptor 9 stimulation increases antitumor immune responses and tumor clearance10.1038/mt.2012.137 ↗
35. GAMER-Ad: a novel and rapid method for generating recombinant adenoviruses10.1016/j.omtm.2021.01.014 ↗
36. A proposed model membrane and test method for microneedle insertion studies10.1016/j.ijpharm.2014.05.042 ↗
37. Transdermal delivery of molecules is limited by full epidermis, not just stratum corneum10.1007/s11095-012-0946-7 ↗
38. Skin biomechanics: breaking the dermal barriers with microneedles
39. Exact prediction of a natural T cell epitope10.1002/eji.1830211136 ↗
40. Trends of microneedle technology in the scientific literature, patents, clinical trials and internet activity10.1016/j.biomaterials.2020.120491 ↗
41. A measles and rubella vaccine microneedle patch in the Gambia: a phase 1/2, double-blind, double-dummy, randomised, active-controlled, age de-escalation trial10.1016/S0140-6736(24)00532-4 ↗
42. Peptide vaccine-treated, long-term surviving cancer patients harbor self-renewing tumor-specific CD8+ T cells10.1038/s41467-022-30861-z ↗
43. Microneedles for painless transdermal immunotherapeutic applications10.1016/j.jconrel.2020.12.019 ↗
44. Effector CD8 T cells dedifferentiate into long-lived memory cells10.1038/nature25144 ↗
45. Tumor-infiltrating lymphocytes in the immunotherapy era10.1038/s41423-020-00565-9 ↗
46. The yin and yang of co-inhibitory receptors: toward anti-tumor immunity without autoimmunity10.1038/s41422-020-0277-x ↗
47. Antigen presentation by dendritic cells for B cell activation10.1016/j.coi.2019.04.003 ↗
48. Transdermal microneedles alleviated rheumatoid arthritis by inducing immune tolerance via skin‐resident antigen presenting cells
49. Microneedle-assisted vaccination combined with autophagy regulation for antitumor immunotherapy10.1016/j.jconrel.2023.04.031 ↗
50. Differential dual‐release bilayer microneedles loaded with aluminum adjuvants as a safe and effective vaccine platform10.1002/adfm.202201952 ↗
51. Type I IFN activating type I dendritic cells for antitumor immunity10.1158/1078-0432.CCR-20-2564 ↗
52. cDC1 prime and are licensed by CD4+ T cells to induce anti-tumour immunity10.1038/s41586-020-2611-3 ↗
53. PeptiVAX: a new adaptable peptides-delivery platform for development of CTL-based, SARS-CoV-2 vaccines10.1016/j.ijbiomac.2024.129926 ↗
54. Advances in COVID-19 mRNA vaccine development10.1038/s41392-022-00950-y ↗
55. Exploring new frontiers in drug delivery with minimally invasive microneedles: fabrication techniques, biomedical applications, and regulatory aspects10.1080/17425247.2023.2201494 ↗
56. How can microneedles overcome challenges facing transdermal drug delivery?10.4155/tde-2017-0028 ↗
57. Dissolving microneedles: applications and growing therapeutic potential10.1016/j.jconrel.2022.05.045 ↗
58. The role of 3D printing technology in microengineering of microneedles10.1002/smll.202106392 ↗